Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
On Demand
Back
Favorite
Facebook
Tweet
Print
Rohini Beavon, PhD
AstraZeneca, United Kingdom
Disclosure(s): AstraZeneca: Employee, holds or may hold stock
Poster(s):
(P-1960) Safety and Pharmacokinetics of Long-acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442) are Consistent after Repeat Dosing: Results from the PROVENT Substudy
Saturday, October 19, 2024
12:15 PM – 1:30 PM
US PT
(P-1969) Safety, Immunogenicity, and Pharmacokinetics of Repeat Dosing with AZD7442 (Tixagevimab/Cilgavimab): Final Analysis of the ENDURE Phase 2, Dose-Ranging Study in Immunocompromised Participants
Saturday, October 19, 2024
12:15 PM – 1:30 PM
US PT
